Almirall registers Phase 3b trial of lebrikizumab in face and neck atopic dermatitis
The study plans to enroll 230 participants and is expected to start in November 2026. It aims to evaluate the efficacy and safety of lebrikizumab for up to 32 weeks in adults and adolescents with moderate-to-severe face and neck atopic dermatitis who also have moderate-to-severe AD elsewhere and need systemic therapy.
Primary source
ClinicalTrials.gov registry record, October 14, 2026
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
Read the source: A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation